About 3D Signatures
3D Signatures is a publicly listed company based in Winnipeg (Canada) founded in 2011. It operates as a diagnostic tools for precision medicine via genomic imaging are provided. 3D Signatures offers products and services including TeloViewSMM, TeloViewNDMM, TeloMRD-D, and TeloViewNG-MRD. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Guardant Health, Alere, Denali Therapeutics, Foundation Medicine and ArcherDX and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Provider of diagnostic tools using genomic imaging for precision medicine. Its proprietary genomic imaging software analyzes 3D microscopy images for centromere arrangement and telomere length. This helps the determination of patient disease prognosis and response to treatment. Their diagnostic solution is a prognostic tool for Hodgkins lymphoma. In addition, the company is also developing diagnostic tools for prostate cancer, multiple myeloma, breast cancer, lung cancer, and Alzheimers disease. 3D Signatures plans to offer its non-invasive blood tests through a network of partner labs as a hybrid SaaS model.
- Headquarters Winnipeg, Canada
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website 3dsignatures.com
- Social X
- Latest Funding Round$1.62M (USD), Post-IPO
Dec 2017
- InvestorsKnight Therapeutics
& 1 more
Products & Services of 3D Signatures
3D Signatures offers a comprehensive portfolio of products and services, including TeloViewSMM, TeloViewNDMM, TeloMRD-D, and TeloViewNG-MRD.
Assesses risk of multiple myeloma transition for high-risk patients.
Predicts relapse in newly diagnosed multiple myeloma cases.
Enumerates minimal residual disease cells post-transplant.
Profiles instability in MRD cells for cancer monitoring.
Funding Insights of 3D Signatures
- Total Rounds 5
- Last Round Post-IPO — $1.62M
- First Round $1M
(Jun 2016)
- Investors Count 2
All 5 funding rounds of 3D Signatures with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $1.62M | Post-IPO | – | – | – |
| Oct 2017 | $400,198 | Post-IPO | – | – | |
| Dec 2016 | $161,475 | Post-IPO | – | – | – |
| Dec 2016 | $180,000 | Post-IPO | – | – | |
| Jun 2016 | $1M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in 3D Signatures
3D Signatures has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Knight Therapeutics and ScreenCell.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Circulating tumor cells are isolated for oncology applications and analysis. | 2011 | screencell.com | Sarcelles, France | |
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company. | 2014 | gud-knight.com | Westmount, Canada |
Investor details for 3D Signatures
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of 3D Signatures
4 dated milestones of 3D Signatures across 6 years, from founding to its latest funding, stage changes and deals.
- Founded 3D Signatures is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.0M.
- Funding Latest funding round, Post-IPO, of $1.6M.
Competitors of 3D Signatures
3D Signatures has 9 listed competitors in our database, 9 of them funded. They include Guardant Health, Alere, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| alere.com | 1991 | Waltham, United States | $616.22M | 7,011 | Developer of small rapid diagnostic devices for infectious diseases | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of 3D Signatures
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as 3D Signatures (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 3D Signatures
3D Signatures was founded in 2011 and raised its 1st funding round 5 years after it was founded.
3D Signatures is headquartered in Winnipeg, Canada. It is registered at Winnipeg, Manitoba, Canada.
Provider of diagnostic tools using genomic imaging for precision medicine. Its proprietary genomic imaging software analyzes 3D microscopy images for centromere arrangement and telomere length. This helps the determination of patient disease prognosis and response to treatment. Their diagnostic solution is a prognostic tool for Hodgkins lymphoma. In addition, the company is also developing diagnostic tools for prostate cancer, multiple myeloma, breast cancer, lung cancer, and Alzheimers disease. 3D Signatures plans to offer its non-invasive blood tests through a network of partner labs as a hybrid SaaS model.
3D Signatures's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
3D Signatures offers TeloViewSMM, TeloViewNDMM, TeloMRD-D, and TeloViewNG-MRD.
3D Signatures has 2 investors. Key investors include Knight Therapeutics, and ScreenCell.